Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Disposal

9 Jul 2012 07:00

RNS Number : 1722H
Flying Brands Limited
09 July 2012
 



9 July 2012

 

Flying Brands Limited (the "Company")

Sale of certain of the assets of the Garden Division

 

 

The Board is pleased to announce that it has disposed of the assets of the retail business of Gardening Direct to Jersey Choice Marketing Limited (the "Purchaser"), a company associated with Jersey Choice Limited ("Jersey Choice") for a gross consideration of £2.875m of which £2.25m will be satisfied in cash at completion. Payment of the remaining £0.625m will be made in cash on 30 April 2013.

 

The Company had originally intended to continue to operate its Growing and Live Dispatch Business ("GLD") from its property at Retreat Farm but it is now in advanced discussions to lease the greenhouses and dispatch centre at Retreat Farm to Jersey Choice until 30 June 2014. If, as expected, this lease is entered into then GLD will be discontinued.

 

For the year ending 30 December 2011, Gardening Direct generated an operating loss of £0.4 million. The book value of the assets the subject of the Disposal was £0.2 million at 30 December 2011.

 

The proceeds of the disposal will be used to repay creditors and for general working capital purposes. The Company has no bank debt although it does owe £1.0m to Palatine Private Equity being the balance of the deferred consideration outstanding for the acquisition of Flowers Direct, which is repayable on 31 December 2012. The Company retains the freehold of Retreat Farm which was valued earlier this year at £3.3m.

 

The Board is currently considering strategic options for the company and for the maximization of the long-term value of Retreat Farm and will update shareholders at its interim announcement.

 

 

For further information, please contact:

 

Flying Brands Limited 01245 228 300

Stephen Cook, Chief Executive

Stuart Dootson, Group Finance Director

 

Smithfield Consultants  020 7360 4900

John Kiely

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISXVLLBLDFLBBE
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.